Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From AbbVie Inc.

Formycon’s Lucentis Biosimilar Enters Swiss and Canada Markets

Switzerland and Canada mark the first market entries for Formycon’s ranibizumab biosimilar this year, with several anticipated launches in the Middle East later in 2024.

Biosimilars Launches

Lupin Bags First US Rival To $1.6bn Ingrezza – But Launch Will Have To Wait

Lupin has claimed the first US approval for an Ingrezza generic – but must wait well over a decade before launching its version of valbenazine, after last year striking a patent litigation settlement with originator Neurocrine Biosciences.

Approvals Generic Drugs

Estonian Biobank’s Personalized Medicine Project To Unlock New Insights For Drug R&D

A new center for personalized medicine in Estonia will see PacBio’s long-read whole genome sequencing technology used to unlock new information about how genetics impact patients’ drug responses, experts from the project tell the Pink Sheet.

Medical Device BioPharmaceutical

Pharma On The Hunt For Oncology Partners Across Modalities

The Inaugural AACR Oncology Industry Partnering Event gave pharma firms an opportunity to tell potential cancer drug collaborators what they need from external sources.

Deals Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Luminera
    • Mavupharma
    • Pharmacyclics, Inc.
    • Stemcentrx, Inc.
    • Syndesi Therapeutics SA
UsernamePublicRestriction

Register